Acute Myeloid Leukemia (AML) Treatment Market Trends
Growth Drivers
- Integration of personalized medicine - In acute myeloid leukemia, precision medicine is used by molecular profiling to identify specific genetic mutations and unique biomarkers for each patient.
To achieve a more personalized and precise approach to AML management, information guides the selection of targeted therapies and tailored treatment plans, optimizing the effectiveness of interventions and minimizing adverse reactions.
According to a study conducted four years ago by The Leukemia & Lymphoma Society (LLS), patients with acute myeloid leukemia (AML) who received precision medicine had better survival outcomes and a much lower early death rate and fared far better than individuals who started therapy early in life. - Development of advanced treatment options - Several research studies are being carried out to show the medications' efficacy, thus resulting in the development of advanced treatment options with a better understanding of acute myeloid leukemia (AML).
For instance, research named 'Daunorubicin or Idarubicin with Cytarabine Plus Quizartinib vs. Physician's Selection in Newly Acquired FLT3-ITD+ AML (Q-SOC)' is now in Phase III clinical trials, according to the United States National Library of Medicine.
Challenges
- Lack of awareness and education - There may still be gaps in knowledge and understanding between healthcare professionals, patients, and the public despite efforts to increase awareness about AML. Delayed diagnosis, insufficient treatment decisions, and poor patient outcomes can be associated with low awareness.
- Resistance to conventional therapies - Due to a high percentage of treatment failure brought on by an increase in the prevalence of medication resistance that causes disease relapse, AML continues to be the primary cause of leukemia-related mortality.
Relapsed and refractory AML is linked to a poor prognosis because of an inadequate response to traditional antileukemic therapy led by the altered-functioning proteins and enzymes, signaling pathway dysregulation, mutations in cell cycle control genes, epigenetic modifiers, and microRNA.
Acute Myeloid Leukemia Market: Key Insights
Regionally, the global AML treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Among the market in these regions, the market in North America is anticipated to account for the largest share by the end of 2029 in the global acute myeloid leukemia treatment market. Increased government funding in R&D activities, a well-developed public healthcare sector and elevated disposable income of the people in the region are the major factors expected to drive the market growth during the forecast period. According to the data by the World Health Organization (WHO), as of 2018, 16.416 % of the GDP is spent on health sector in North America. Moreover, people-friendly medical reimbursement policies are also estimated to boost the market growth in North America. The market in Europe, on the other hand, is estimated to be a promising market owing to the high healthcare expenditure in the region. Moreover, the growth of the market is encouraged by the availability of a large geriatric population in the region. As of 2019, over 20% of the total population in Southern Europe was aged 65 years and above.
Moreover, the market share of Asia Pacific is expected to grow notably during the forecast period due to the enormous unmet potential present in the healthcare sector of the region. The rapid economic development combined with a growing demand for advanced healthcare system is likely to encourage considerable growth for the APAC region.
The global AML treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.6% |
|
Base Year Market Size |
USD 3.41 billion |
|
Forecast Year Market Size |
USD 12.63 billion |
|
Regional Scope |
|
